Korea Investment CORP Boosts Stock Holdings in Solventum Co. (NYSE:SOLV)

Korea Investment CORP lifted its position in shares of Solventum Co. (NYSE:SOLV) by 1.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 120,707 shares of the company’s stock after purchasing an additional 1,400 shares during the quarter. Korea Investment CORP owned about 0.07% of Solventum worth $7,974,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SOLV. Worldquant Millennium Advisors LLC boosted its position in Solventum by 373.6% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after purchasing an additional 37,600 shares during the period. Harbor Capital Advisors Inc. boosted its position in shares of Solventum by 24.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after buying an additional 9,333 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Solventum by 37.4% in the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after buying an additional 32,051 shares during the period. State Street Corp raised its holdings in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after buying an additional 185,938 shares during the period. Finally, Forsta AP Fonden acquired a new position in Solventum during the 4th quarter worth approximately $1,876,000.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Wells Fargo & Company increased their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Piper Sandler lifted their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Mizuho upped their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Morgan Stanley raised their target price on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Finally, The Goldman Sachs Group boosted their price target on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Stock Up 1.7 %

Shares of Solventum stock opened at $76.02 on Tuesday. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm has a market cap of $13.15 billion and a P/E ratio of 27.64. The business has a 50-day moving average price of $75.56 and a 200 day moving average price of $71.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.